PCSK9-IN-10
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.
Product Specifications
CAS Number
368434-98-4
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
373.41
Molecular Formula
C18H23N5O4
Notes
Research use only, not for human use.
Receptor
Serine/threonin kinase
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
